U.S. Stem Cell (USRM) 10-Q 6 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 05, 2019
Document Information Line Items
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		407,109,995
Amendment Flag	false
Entity Central Index Key	0001388319
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Interactive Data Current	Yes

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 78,104	$ 1,357,146
Accounts receivable, net	20,245	18,035
Inventory	46,351	93,215
Prepaid and other	38,128	38,128
Total current assets	182,828	1,506,524
Property and equipment, net	87,659	242,615
Right to use assets	375,593	0
Investments	0	57,790
Deposits	10,160	10,160
Total assets	656,240	1,817,089
Current liabilities:
Accounts payable, including $3,167 and $75,714 to related parties, respectively	1,112,280	1,182,730
Accrued expenses	1,142,140	1,155,792
Advances, related party	374,901	234,901
Deferred revenue	183,525	293,665
Deferred gain on sale of equipment	53,686	128,845
Deposits	565,286	465,286
Promissory note, long term portion, net of debt discount of $46,911	1,350,851	0
Notes payable, related party	2,579,365	1,993,104
Notes and capital leases payable, net of debt discount of $36,032 and $62,240, respectively	1,512,227	462,330
Lease liability	59,970	0
Total current liabilities	8,934,231	5,916,653
Long term debt:
Deferred revenue	63,250	65,500
Deferred gain on sale of equipment	0	21,474
Long term deposits	0	100,000
Lease liability, long term portion	316,075	0
Promissory note, long term portion, net of debt discount of $99,183	0	1,298,579
Notes and capital leases payable, long term portion, net of debt discount of $0 and $12,413, respectively	456,496	1,297,093
Total long-term debt	835,821	2,782,646
Total liabilities	9,770,052	8,699,299
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, -0- issued and outstanding as of September 30, 2019 and December 31, 2018	0	0
Common stock, par value $0.001; 2,000,000,000 shares authorized, 397,743,960 and 378,076,976 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	397,744	378,077
Additional paid in capital	123,435,415	122,528,391
Accumulated deficit	(132,946,971)	(129,788,678)
Total stockholders' deficit	(9,113,812)	(6,882,210)
Total liabilities and stockholders' deficit	$ 656,240	$ 1,817,089

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accounts payable, related parties (in Dollars)	$ 3,167	$ 75,714
Promissory note, long term portion, debt discount (in Dollars)	46,911
Debt discount (in Dollars)	$ 36,032	$ 74,653
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	397,743,960	378,076,976
Common stock, shares outstanding	397,743,960	378,076,976
Note and Capital Lease Payables [Member]
Debt discount (in Dollars)	$ 36,032	$ 62,240
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)		99,183
Note and Capital Lease Payables [Member]
Debt discount (in Dollars)	$ 0	$ 12,413

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Revenue	$ 156,591	$ 1,503,884	$ 2,763,385	$ 5,037,242
Cost of sales	137,366	544,398	1,165,459	1,615,431
Gross profit	19,225	959,486	1,597,926	3,421,811
Cost and operating expenses:
Research and development	0	599	263	4,527
Marketing, general and administrative	1,616,970	1,177,638	3,628,652	4,468,121
Pre-litigation settlement	0	0	500,000	0
Depreciation and amortization	0	0	0	524
Total operating expenses	1,616,970	1,178,237	4,128,915	4,473,172
Loss from operations	(1,597,745)	(218,751)	(2,530,989)	(1,051,361)
Other income (expenses):
Gain on settlement of debt	33,203	80,200	21,892	45,013
Gain on sale of equipment	32,211	32,211	96,634	96,634
Miscellaneous income	11,000	0	11,069	0
(Loss) income from equity investment	(33,478)	160,216	93,778	263,322
Interest expense	(91,140)	(384,813)	(850,677)	(1,068,238)
Total other income (expenses)	(48,204)	(112,186)	(627,304)	(663,269)
Net loss before income taxes	(1,645,949)	(330,937)	(3,158,293)	(1,714,630)
Income taxes (benefit)	0	0	0	0
NET LOSS	$ (1,645,949)	$ (330,937)	$ (3,158,293)	$ (1,714,630)
Net loss per common share, basic and diluted (in Dollars per share)	$ 0	$ 0	$ (0.01)	$ 0
Weighted average number of common shares outstanding, basic and diluted (in Shares)	396,637,920	368,188,089	392,029,562	362,461,973
Product [Member]
Revenue:
Revenue	$ 28,160	$ 276,281	$ 299,826	$ 1,414,571
Service [Member]
Revenue:
Revenue	127,456	1,227,603	2,412,808	3,622,671
Management Fees-related Party [Member]
Revenue:
Revenue	$ 975	$ 0	$ 50,751	$ 0

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock Subscriptions [Member]	Total
Balance at Dec. 31, 2017	$ 342,113	$ 120,185,821	$ (127,628,251)		$ (7,100,317)
Balance (in Shares) at Dec. 31, 2017	342,113,098
Common stock issued in settlement	$ 3,818	143,895			147,713
Common stock issued in settlement (in Shares)	3,817,783
Common stock issued for services	$ 4,366	237,265			241,631
Common stock issued for services (in Shares)	4,366,274
Proceeds from issuance of common stock	$ 8,429	314,571			323,000
Proceeds from issuance of common stock (in Shares)	8,428,658
Common stock subscription				$ 44,700	44,700
Stock based compensation		82,555			82,555
Net loss			(139,159)		(139,159)
Balance at Mar. 31, 2018	$ 358,726	120,964,107	(127,767,410)	44,700	(6,399,877)
Balance (in Shares) at Mar. 31, 2018	358,725,813
Balance at Dec. 31, 2017	$ 342,113	120,185,821	(127,628,251)		(7,100,317)
Balance (in Shares) at Dec. 31, 2017	342,113,098
Net loss					(1,714,630)
Balance at Sep. 30, 2018	$ 368,318	121,935,624	(129,342,881)		(7,038,939)
Balance (in Shares) at Sep. 30, 2018	368,318,188
Balance at Mar. 31, 2018	$ 358,726	120,964,107	(127,767,410)	44,700	(6,399,877)
Balance (in Shares) at Mar. 31, 2018	358,725,813
Common stock issued in settlement	$ 3,241	201,256			204,497
Common stock issued in settlement (in Shares)	3,241,779
Common stock issued for services	$ 3,500	154,400			157,900
Common stock issued for services (in Shares)	3,500,000
Proceeds from issuance of common stock	$ 922	43,778		$ (44,700)
Proceeds from issuance of common stock (in Shares)	921,650
Related party contribution to equity investment		103,159			103,159
Stock based compensation		137,069			137,069
Net loss			(1,244,534)		(1,244,534)
Balance at Jun. 30, 2018	$ 366,389	121,603,769	(129,011,944)		(7,041,786)
Balance (in Shares) at Jun. 30, 2018	366,389,242
Common stock issued in settlement	$ 1,929	51,960			53,889
Common stock issued in settlement (in Shares)	1,928,946
Fair value of warrants issued for compensation		24,986			24,986
Related party contribution to equity investment		86,750			86,750
Stock based compensation		168,159			168,159
Net loss			(330,937)		(330,937)
Balance at Sep. 30, 2018	$ 368,318	121,935,624	(129,342,881)		(7,038,939)
Balance (in Shares) at Sep. 30, 2018	368,318,188
Balance at Dec. 31, 2018	$ 378,077	122,528,391	(129,788,678)		(6,882,210)
Balance (in Shares) at Dec. 31, 2018	378,076,976
Common stock issued in settlement	$ 8,099	180,862			188,961
Common stock issued in settlement (in Shares)	8,098,929
Common stock issued for services	$ 3,500	82,850			86,350
Common stock issued for services (in Shares)	3,500,000
Related party contribution to equity investment		15,265			15,265
Stock based compensation		169,216			169,216
Net loss			(673,218)		(673,218)
Balance at Mar. 31, 2019	$ 389,676	122,976,584	(130,461,896)		(7,095,636)
Balance (in Shares) at Mar. 31, 2019	389,675,905
Balance at Dec. 31, 2018	$ 378,077	122,528,391	(129,788,678)		$ (6,882,210)
Balance (in Shares) at Dec. 31, 2018	378,076,976
Common stock issued for services (in Shares)					3,500,000
Net loss					$ (3,158,293)
Balance at Sep. 30, 2019	$ 397,744	123,435,415	(132,946,971)		(9,113,812)
Balance (in Shares) at Sep. 30, 2019	397,743,960
Balance at Mar. 31, 2019	$ 389,676	122,976,584	(130,461,896)		(7,095,636)
Balance (in Shares) at Mar. 31, 2019	389,675,905
Common stock issued in settlement	$ 4,019	85,201			89,220
Common stock issued in settlement (in Shares)	4,018,915
Stock based compensation		169,216			169,216
Net loss			(839,126)		(839,126)
Balance at Jun. 30, 2019	$ 393,695	123,231,001	(131,301,022)		(7,676,326)
Balance (in Shares) at Jun. 30, 2019	393,694,820
Common stock issued in settlement	$ 4,049	29,964			34,013
Common stock issued in settlement (in Shares)	4,049,140
Stock based compensation		174,450			174,450
Net loss			(1,645,949)		(1,645,949)
Balance at Sep. 30, 2019	$ 397,744	$ 123,435,415	$ (132,946,971)		$ (9,113,812)
Balance (in Shares) at Sep. 30, 2019	397,743,960

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,158,293)	$ (1,714,630)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	154,956	155,480
Bad debt (recoveries)	30,869	32,546
Amortization of discount on debt	141,296	164,312
Gain on settlement of debt	(21,892)	(45,013)
Gain on sale of equipment	(96,634)	(96,634)
Related party notes payable issued for services rendered	800,000	800,000
Income on equity investments	(93,778)	(263,322)
Note payable issued in pre-trial settlement	500,000	0
Stock based compensation	586,382	812,300
Changes in operating assets and liabilities:
Receivables	(33,079)	(22,129)
Inventory	46,864	(2,284)
Deposits	0	0
Prepaid and other current assets	0	(35,000)
Accounts payable	269,070	332,577
Accrued expenses	(4,507)	242,004
Deferred revenue	(112,390)	217,038
Net cash (used in) provided by operating activities	(991,136)	577,245
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from (payments to) equity investments	166,833	214,200
Net cash provided by investing activities	166,833	214,200
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable	0	126,402
Proceeds from sale of common stock	0	367,700
Proceeds from related party advances	140,000	100,000
Equity contribution by related party	0	103,159
Repayments of related party notes	(213,739)	(542,971)
Repayments of notes payable	(381,000)	(484,381)
Net cash used in financing activities	(454,739)	(330,091)
Net (decrease) increase in cash and cash equivalents	(1,279,042)	461,354
Cash and cash equivalents, beginning of period	1,357,146	986,799
Cash and cash equivalents, end of period	78,104	1,448,153
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	633,859	808,243
Income taxes paid	0	0
Non cash financing activities:
Common stock issued in settlement of notes payable	0	406,099
Equity contributed to investment	15,265	86,750
Record right-to-use assets and related lease liability	$ 383,351	$ 0

NOTE 1 - SIGNIFICANT ACCOUNTING

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows: General The accompanying unaudited condensed financial statements of U.S. Stem Cell, Inc. (the “Company”) have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three- and nine-month periods ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ended December 31, 2019. The unaudited condensed financial statements should be read in conjunction with the December 31, 2018 audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K. Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the sector of the cell technology industry delivering cell therapies and biologics that help address a variety of injuries and diseases such as osteoarthritis, heart failure, lower limb ischemia, neurological conditions, autoimmune diseases and other issues. The primary business includes the development of proprietary cell therapy procedure and products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, revenues realized from an Asset Sale and Lease Agreement related to the segment of the Company business involving collecting, growing and banking cell cultures and treatment kits for humans and animals), and the operation of a cell therapy clinic (subsequently limited by the Order of Permanent Injunction, see below ). To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. In addition, the recent Order of Permanent Injunction arising from the action brought by the Department of Justice (see Note 11), has resulting in management considering modifications to the Company business model in order to offset the loss of revenue resulting from the consequences of this Injunctive Order. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. Revenue Recognition Effective January 1, 2018, the Company recognizes revenue in accordance with Accounting Standards Codification 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from in-person trainings are recognized when the training occurs and revenues from on demand online trainings are recognized when the customer purchases the rights to the training course. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as multiple performance obligations as described in ASC 606 and addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on stand-alone pricing. The multiple performance obligations include stem cell banking, dose retrieval and yearly storage fees. Revenues for stem cell banking and dose retrieval is recognized at the point of service and revenues for the yearly storage fees is recognized over the term of the banking contract, which is typically one year with annual renewals. Revenues have been adversely impacted by the Order of Permanent Injunction (see the Notes herein including Note 10). At September 30, 2019 and December 31, 2018, the Company had deferred revenues of $246,775 and $293,665, respectively, which includes $63,250 and $68,500, respectively, to the Intellectual Property Licensing Agreement. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2019, and December 31, 2018, allowance for doubtful accounts was $13,203 and $30,808, respectively. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 49.9 percent member interest ownerships of U.S. Stem Cell Clinic, LLC and Regenerative Wellness Clinic, LLC respectively and its 49 percent member interest ownership of U.S. Stem Cell Clinic of the Villages utilizing the equity method of accounting (See Note 3). Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years. Equipment under capital leases are recorded at the estimated present value of the minimum lease payments. Equipment under capital leases are amortized over the term of the lease, which is three years. Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2019 and 2018 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2019 September 30, 2018 Options to purchase common stock 121,038,655 103,970,693 Warrants to purchase common stock 1,112,251 1,118,019 Totals 122,150,906 105,088,712 Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2019, two customers represented 55% and 21%, respectively, representing an aggregate of 76% of the Company’s accounts receivable. As of December 31, 2018, four customers represented 41%, 10%, 16% and 10% respectively, representing an aggregate of 77% of the Company’s accounts receivable. For the three months ended September 30, 2019, the Company’s revenues earned from sale of products and services were $156,591, of which three customers, one a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 49.9% interest) represented 27%, 21% and 11% (related party). For the three months ended September 30, 2018, the Company’s revenues earned from sale of products and services were $1,503,884, of which two customers represented 12% and 10%, respectively, one of which is a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 49% interest) represented 12% of Company’s revenue. For the nine months ended September 30, 2019, the Company’s revenues earned from sale of products and services were $2,763,385, of which one customer represented, a related party, (US Stem Cell Clinic LLC, a partly owned investment in with the Company holds a 49.9% interest), represents 12% of Company’s revenue. For the nine months ended September 30, 2018, the Company’s revenues earned from sale of products and services were $5,037,242, of which two customers represented 11% and 8% respectively, of Company’s revenue, one of which is a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company held a 49.9% interest) represented 11%. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $0 and $263 for the three and nine months ended September 30, 2019, respectively; and $599 and $4,527 for the three and nine months ended September 30, 2018, respectively. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Deposits Deposits are comprised of the following: On March 3, 2017, the Company entered into a customer purchase agreement with General American Capital Partners (GACP), whereby the Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 8). On March 3, 2017, the Company entered into an asset purchase agreement of intellectual property with GACP whereby the Company agreed to sell all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell banking business for $50,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 8). As a consequence of the Court Order (see Note 10), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into a Termination and Release Agreement and a Letter Agreement intended to divested itself of certain equipment and other assets underlying the related equipment lease transaction (see Notes, 4, and 8). Adoption of Accounting Standards In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new ROU assets and lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, the Company recognized additional operating lease liabilities, net of deferred rent, of approximately $57,000 based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $57,000. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Beginning in 2019, the Company changed to its disclosed lease recognition policies and practices, as well as to other related financial statement disclosures due to the adoption of this standard. See Note 5. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 — GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements for nine months ended September 30, 2019, the Company incurred net losses of $3,158,293 and has a working capital deficit (current liabilities in excess of current assets) of $8,751,403. These factors among others raise substantial doubts about the Company’s ability to continue as a going concern for a reasonable period. The Company’s primary source of operating funds in the past has been from revenue generated from sales and cash proceeds from the sale of common stock and the issuance of convertible and other debt. The Company has experienced net losses and negative cash flows from operations since inception and has been hindered by the recent Order of Permanent Injunction resulting from the action brought by the Department of Justice (see Note 10). Under the current business model, the Injunction is likely to significantly reduce the Company’s future revenues. As a consequence of the Court Order (see Note 10), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into a Termination and Release Agreement and a Letter Agreement intended to divested itself of certain equipment and other assets underlying the related equipment lease transaction (see Notes, 4, and 8). Management is considering modifications to the Company business model in order to offset the loss of revenue resulting from the consequences of this Injunctive Order. As of the date herein, no specific undertakings have commenced. The Company has stockholders’ deficiencies at September 30, 2019 and requires additional financing to fund future operations. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts or revenues realized from the Asset Sale and Lease Agreement will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 3 - INVESTMENTS

NOTE 3 - INVESTMENTS	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 — INVESTMENTS U.S. Stem Cell Clinic, LLC The investment in U.S. Stem Cell Clinic, LLC is comprised of a 49.9% (33.3% in 2018) member interest ownership and is accounted for using the equity method of accounting. The Company’s 49.9% (33.3% in 2018) income (loss) earned by U.S. Stem Cell Clinic, LLC member interests was $(20,637) and $51,514 for the three and nine months ended September 30, 2019 and $82,950 and $171,740 for the three and nine months ended September 30, 2018, respectively (inception to date income of $599,721) which was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods. In addition, during the nine months ended September 30, 2019 and 2018, the Company received distributions totaling $64,870 and $154,000 from U.S. Stem Cell Clinic, LLC, respectively (inception to date of $663,870). The carrying value of the investment at September 30, 2019 and December 31, 2018 is $0 and $8,921, respectively. At September 30, 2019 and December 31, 2018, accounts receivable for sales of product and services to U.S. Stem Cell Clinic, LLC was $0; revenues earned from sales to U.S. Stem Clinic, LLC for the three and nine months ended September 30, 2019 were $33,614 and $329,003, and the three and nine months ended September 30, 2018 were $183,832 and $529,880, respectively. In January 2019, a member of U.S. Stem Cell Clinic, LLC contributed 16.6% of his ownership interest to the Company increasing the Company’s member interest from 33.3% to 49.9%. The Company recorded the contribution to equity of $4,435. An affiliate of one of the Company’s former officers is an investor in the U.S. Stem Cell Clinic, LLC. Regenerative Wellness Clinic, LLC The investment in Regenerative Wellness Clinic, LLC is comprised of a 49.9% (33.3% in 2018) member interest ownership and is accounted for using the equity method of accounting. The Company has provided technical expertise, but no cash investment with Regenerative Wellness Clinic, LLC’s startup in 2017. The Company’s 49.9% (33.3% in 2018) income (loss) earned by Regenerative Wellness Clinic, LLC member interests was $(2,910) and $69,345 for the three and nine months ended September 30, 2019 and for the three and nine months ended September 30, 2018 was $58,931 and $73,247 reported, after effects of 2017 loss, of $9,695, respectively (inception to date income of $113,047) which was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods. In addition, during the nine months ended September 30, 2019 and 2018, the Company received distributions totaling $101,963 and $21,000 from Regenerative Wellness Clinic, LLC, respectively (inception to date of $101,963). The carrying value of the investment at September 30, 2019 and December 31, 2018 is $0 and $21,787, respectively. At September 30, 2019 and December 31, 2018, accounts receivable for sales of products and services to Regenerative Wellness Clinic, LLC was $0; revenues earned from sales to Regenerative Wellness Clinic, LLC for the three and nine months ended September 30, 2019 was $16,637 and $132,984 and for the three and nine months ended September 30, 2018 was $64,945 and $149,469, respectively. In January 2019, a member of Regenerative Wellness Clinic, LLC contributed 16.6% of his ownership interest to the Company increasing the Company’s member interest from 33.3% to 49.9%. The Company recorded the contribution to equity of $10,830. An affiliate of one of the Company’s former officers is an investor in the Regenerative Wellness Clinic, LLC. U.S. Stem Cell Clinic of the Villages LLC On January 30, 2018, Greg Knutson, a director of the Company (“Knutson”) and the Company agreed to open and operate a regenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases in Florida. To that end, U.S. Stem Cell Clinic of The Villages LLC (the “LLC”) was formed on January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the LLC. Currently, Knutson holds a 51%-member interest in the LLC and the Company holds a 49%-member interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the LLC gross revenues. As of December 31, 2018, upon completion of the LLC, the Company was credited with investment equity of $86,750 from Greg Knutson, the holder of the 51%-member interest. The Company then recorded the investment equity as contributed capital by the Company. The Company’s 49% income (loss) incurred by the LLC member interests was $(9,931) and $(27,081) for the three and nine months ended September 30, 2019 and $18,335 for three and nine months ended September 30, 2018, respectively. In addition, during the year ended December 31, 2018, the Company received distributions totaling $63,700 from the LLC. The carrying value was $0 and $27,081 at September 30, 2019 and December 31, 2018, respectively At September 30, 2019 and December 31, 2018, accounts receivable for sales of products and services to the LLC was $0; revenues earned from sales to the LLC for the three and nine months ended September 30, 2019 was $9,975 and $140,328 and for the three and nine months ended September 30, 2018 was $64,074 and $143,550, respectively. During the three and nine months ended September 30, 2019, the Company received $975 and $50,751 management fees from the LLC, respectively.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long-lived assets. Property and equipment as of September 30, 2019 and December 31, 2018 is summarized as follows: September 30, 2019 December 31, 2018 Laboratory and medical equipment $ 5,590 $ 5,590 Furniture, fixtures and equipment 125,633 125,633 Computer equipment 49,951 49,951 Equipment under capital lease 624,602 624,602 Leasehold improvements 362,046 362,046 1,167,822 1,167,822 Less accumulated depreciation and amortization (1,080,163 ) (925,207 ) $ 87,659 $ 242,615 On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction, the “Asset Sale and Lease Agreement”) with GACP, whereby the Company sold certain lab, medical and other equipment relating to the cell banking business for $400,000 and leased back the sold equipment over a three-year term. The Company determined that the transaction was a capitalized lease and accordingly recorded the leased assets and liability based on the estimated present value of the minimum lease payments. Included in net property are assets under capital leases of $624,602, less accumulated depreciation of $533,738 as of September 30, 2018 and $624,602, less accumulated depreciation of $383,559 December 31, 2018, respectively. In connection with the sale of the lab, medical and other equipment, the Company realized a gain on sale of equipment of $386,535. The gain is recognized ratably over the term of the lease to operations. During the three and nine months ended September 30, 2019, the Company recognized $32,211 and $96,634; and $32,211 and $96,634 during the three and nine months ended September 30, 2018, as the gain on sale of equipment, respectively. As of September 30, 2019, and December 31, 2018, deferred gain on sale of equipment was $53,686 and $150,319, respectively. As a consequence of the Court Order (see Note 10), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into a Termination and Release Agreement and a Letter Agreement intended to divest itself of certain equipment and other assets underlying the related equipment lease transaction (see Note 8). Property and equipment are recorded based on cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. Depreciation expense was $51,652 and $154,956 of which $51,652 and $154,956 were included in cost of sales for the three and nine months ended September 30, 2019, respectively. Depreciation expense was $51,652 and $155,480 of which $51,652 and $154,956 were included in cost of sales for the three and nine months ended September 30, 2018, respectively.

NOTE 5 - RIGHT TO USE ASSETS AN

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY	9 Months Ended
	Sep. 30, 2019
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 5 — RIGHT TO USE ASSETS AND LEASE LIABILITY The Company leases its headquarters in Sunrise, Florida which consists of 4,860 square feet of space, which it leases at a current rent of approximately $82,620 per year. In September 2013, the Company amended its facility lease to extend the term until July 31, 2016. On February 4, 2016, the Company extended its facility lease to extend the term of the lease until August 31, 2019 at a monthly base rent of $7,306 plus a pro rata share of landlord’s operating expenses. Effective September 1, 2019, the Company entered into a second amendment to the above described lease to extend the premises through August 31, 2014 with base rent beginning at $87,674 per year and escalating to $98,678 per year plus a pro rata share of the landlord’s operating expenses. At lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8% and determined their initial present values, at inception, of $383,351. In determining the length of the lease term to its long-term lease, the Company determined there was not an option to extend the lease. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. In determining the length of the lease term to its long-term lease, the Company determined there was not an option to extend the lease. At lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8% and determined the initial present value, at inception, of $274,180. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right to use assets of $56,734 and lease liability of $56,734. Right to use assets is summarized below: September 30, 2019 Sunrise Facility $ 383,351 Less accumulated depreciation (7,758 ) Right to use assets, net $ 375,593 During the three and nine months ended September 30, 2019, the Company recorded $34,560 and $105,885 as lease expense to current period operations, respectively. Lease liability is summarized below: September 30, 2019 Sunrise, FL $ 376,045 Less: short term portion (59,970 ) Long term portion $ 316,075 Maturity analysis under these lease agreements are as follows: Three months ended December 31, 2019 $ 21,919 Year ended December 31, 2020 88,551 Year ended December 31, 2021 91,208 Year ended December 31, 2022 93,944 Year ended December 31, 2023 96,762 Year ended December 31, 2024 65,786 458,170 Less: Present value discount (82,125 ) Lease liability $ 376,045 Lease expense for the three months ended September 30, 2019 was comprised of the following: Operating lease expense $ 34,560 Variable lease expense - $ 34,560 Lease expense for the nine months ended September 30, 2019 was comprised of the following: Operating lease expense $ 105,200 Variable lease expense 685 $ 105,885

NOTE 6 - ACCRUED EXPENSES

NOTE 6 - ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 — ACCRUED EXPENSES Accrued expenses consisted of the following as of September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank $ 422,934 $ 347,235 Interest payable on notes payable-related party (See Note 8) 555,571 482,784 Vendor accruals and other 146,420 146,420 Payroll and related expenses 14,837 - Marketing obligation 2,378 179,353 $ 1,142,140 $ 1,155,792 During the nine months ended September 30, 2019, the Company issued an aggregate of 16,166,984 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred a $23,168 net gain in settlement of debt.

NOTE 7 - NOTES AND CAPITAL LEAS

NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 — NOTES AND CAPITAL LEASE PAYABLE Notes and capital lease payable were comprised of the following as of September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams note(s) payable 394,500 444,000 Weider promissory note payable 491,525 - Power Up Lending Group notes payable 40,838 145,476 Lab and medical equipment capitalized leases 97,892 264,590 Total notes payable 2,004,785 1,834,076 Less unamortized debt discount (36,032 ) (74,653 ) Total notes payable net of unamortized debt discount 1,968,753 1,759,423 Less current portion (1,512,227 ) (462,330 ) Long term portion $ 456,496 $ 1,297,093 Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2019 to extend the maturity date to May 18, 2020. Hunton & Williams Notes At December 31, 2016, the Company had two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar Biotech Group, LLC (or successor) Loan is paid off. On August 31, 2017, the Company and the note holder entered into a Note Forbearance, Modification and Repayment Agreement (“Agreement”). The two notes, $61,150 and $323,822, were payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring. The total of unpaid principal and accumulated interest for both notes as of August 31, 2017 was $747,680 and an account payable of $40,596, for an aggregate total of $788,276. The note holder agreed to accept full payment of their obligation of over a four (4) year period in 48 monthly installments on an adjusted debt obligation in aggregate of $624,000 (reducing the outstanding balance), with such payments staggered in amounts such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the note holder agreed to suspend accrual interest on the notes commencing September 1, 2017. The Agreement remains in full force and effect provided the Company continues to make the monthly payments, there is no event of default as defined in the notes and an agreement to a subordination agreement by Northstar Biotech Group, LLC, which has been provided. During the nine-month ended September 30, 2019, the Company did not make all required payments. However, the noteholder agreed to waive their default rights under the agreement for a payment commitment of $5,000 in December 2019. The Company imputed an interest rate of 5% and discounted the note accordingly. The imputed debt discount of $69,700 is amortized to interest expense using the effective interest method. The imputed debt discount of $69,700 is amortized to interest expense using the effective interest method. For three and nine months ended September 30, 2019, the Company amortized $24,205 and $34,945, and for three and nine months ended September 30, 2018, the Company amortized $6,343 and $22,426 of debt discounts to current period operations as interest expense. At September 30, 2019, the Company is in default and is negotiating payment structure. The remaining unamortized debt discount at September 30, 2019 was charged to current period operations. Weider Promissory Note The Company, as one of the parties entered into a Settlement Agreement and General Release (the “Agreement”) dated June 3, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% unsecured promissory note, dated June 15, 2019, in the principal amount of $500,000, payable in monthly increments of $5,000 per month, with a final balloon payment due on June 15, 2024. The Company recorded the promissory note to current period operations. Remaining outstanding balance as of September 30, 2019 was $491,525. PowerUp Lending Group, Ltd On November 8, 2018, the Company entered into a revenue based factoring agreement and received an aggregate of $137,200 (less origination fees of $2,800) in exchange for $187,600 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,276 for 147 business days. The Company received net proceeds of $93,809 along with cancellation of the previous revenue based factoring agreement issued in May 2018. In connection with the cancellation of the January 2018 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $37,604 in 2018. This agreement was subsequently terminated (see below) in exchange for a new revenue based factoring agreement. On April 16, 2019, the Company entered into a revenue based factoring agreement and received an aggregate of $137,200 (less origination fees of $2,800) in exchange for $187,600 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,276 for 147 business days. The Company received net proceeds of $84,876 along with cancellation of the previous revenue based factoring agreement issued in November 2018. In connection with the cancellation of the November 2018 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $1,276 in 2019. The remaining principle balance of the PowerUp Lending Group promissory note payable at September 30, 2019 and December 31, 2018 is $40,838 and $145,486, net of unamortized discount of $36,032 and $43,452, respectively. Lab and Medical Equipment Capitalized Lease On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction; “Asset Sale and Lease Agreement”) with GACP, whereby the Company sold certain lab, medical and other equipment relating to the cell banking business for $400,000 and leased back the sold equipment over a three year term. The Company recognized the arrangement as a capital lease. The Company initially recorded the equipment and the capitalized lease liability at the estimated present value of the minimum lease payments of $619,825. The lease includes a base monthly rental payment of $20,000, due the first day of each calendar month plus contingent rent equal to 2.3%, 22.5%, and 31.6% of revenues collected on deposits arising from cell banking business for years 1, 2 and 3, respectively. The contingent rent is recognized as a period expense and as interest expense at the time of collection. At the expiration of the lease, the Company is required to return all leased equipment and along with any maintenance records, logs, etc. in the Company’s possession to the lessor with no right of repurchase. The Company determined that the present value of the minimum lease payments exceeded 90% of the estimated fair value of the equipment and therefore classified the equipment sale/lease as a capitalized lease. The effective interest rate of the capitalized lease is estimated at 10.00% based on the Company estimated incremental borrowing rate. The following summarizes the assets under capital leases: September 30, 2019 December 31, 2018 Classes of property Lab, medical and other equipment $ 619,825 $ 619,825 Office equipment 4,777 4,777 Less: accumulated depreciation (538,515 ) (383,559 ) $ 86,087 $ 241,043 The following summarizes the current and long-term portion of capital leases: September 30, 2019 December 31, 2018 Current leases payable $ 97,892 $ 225,084 Long-term leases payable - 39,506 Total $ 97,892 $ 264,590 The following summarizes total future minimum lease payments at September 30, 2019: Period ending, Three months ended December 31, 2019 60,000 Year ended December 31, 2020 40,000 Total minimum lease payments 100,000 Amount representing interest (2,108 ) Present value of minimum lease payments 97,892 Current portion of capital lease obligations 97,892 Capital lease obligation, less current portion $ - Promissory note On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt, related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737. The note is unsecured and non-interest bearing with four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 is amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2019, the Company amortized $17,616 and $52,273; and $17,616 and $52,273 for the three and nine months ended September 30, 2018, of debt discounts to current period operations as interest expense, respectively. The unamortized debt discount at September 30, 2019 is $46,911. As of September 30, 2019, the remaining principle due was $1,397,762.

NOTE 8 - RELATED PARTY TRANSACT

NOTE 8 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 — RELATED PARTY TRANSACTIONS Advances As of September 30, 2019, and December 31, 2018, the Company’s officers and directors have provided advances in the aggregate of $374,901 and $234,901 respectively, for working capital purposes. The advances are unsecured, due on demand, and non-interest bearing. Notes payable-related party Northstar Biotechnology Group, LLC On February 29, 2012, a promissory note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company at the time, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267 the (“Note”). On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties agreed to modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six-month anniversary of the effective date for any accrued and unpaid interest. On March 1, 2017, Northstar and the Company entered into a settlement agreement (“Settlement Agreement “) related to then pending litigation (See Note 11). Pursuant to the terms and conditions of the Settlement Agreement, Northstar converted its outstanding Series A Convertible preferred stock, into twenty million (20,000,000) shares of common stock according to the original conversion terms. In addition, and separate and apart from the conversion, Northstar received Eleven Million (11,000,000) shares of the Company’s common stock. Northstar will receive ten percent (10%) of all Company international sales (based on a gross sales basis). There was no effect of the 10% obligation as there were no international sales in 2017 or, to date, in 2018 Furthermore, a Northstar designee, Greg Knutson, was appointed as a member of the Board of Directors of the Company and two Company directors, Michael Tomas and Kristin Comella (with Dr. Comella no longer a member of the Board of Directors after September 1, 2019), each exercised their prior Northstar options to each receive a Five percent (5%) Member Interest in Northstar. The parties agreed to a mutual release and Northstar agreed to terminate any UCC lien on the Company assets previously filed for the benefit of Northstar. On March 9, 2017 and April 1, 2017, the Company issued 30,000,000 and 1,000,000 shares of its common stock, respectively, as described above. In connection with the settlement, the Company recorded a loss on litigation settlement of $316,800. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards cash advances. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, the limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such on the condition that Northstar provide certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due April 1, 2016 per the forbearance agreement. On October 6, 2016, the Company issued 848,490 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2016 per the forbearance agreement. On April 1, 2017, the Company issued 286,315 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,703 due April 1, 2017 per the forbearance agreement. On October 2, 2017, the Company issued 559,187 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2017 per the forbearance agreement. On October 19, 2018, the Company issued 164,523 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,195 due October 1, 2018 per the forbearance agreement. On April 19, 2018, the Company issued 379,141 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,145 due April 1, 2019 per the forbearance agreement. As of September 30, 2019, and December 31, 2018, the principal of this note was $262,000. Officer and Director Notes September 30, 2019 December 31, 2018 Note payable, Mr. Tomas $ 161,786 $ 483,393 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Dr. Comella* 255,579 147,711 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 - Total $ 2,317,365 $ 1,731,104 * Dr. Comella is no longer a member of the Board of Directors after September 1, 2019. Notes payable, Mr. Tomas On August 7, 2017, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. During the nine months ended September 30, 2019, the Company paid off $321,607 of the outstanding promissory note. The principal outstanding balance of this note as of September 30, 2019 and December 31, 2018 is $161,786 and $483,393, respectively. On May 7, 2018, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due six months from date of issuance. The principal outstanding balance of this note as of September 30, 2019 and December 31, 2018 is $500,000. On July 1, 2019, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due November 7, 2019. The principal outstanding balance of this note as of September 30, 2019 is $500,000. At September 30, 2019 and December 31, 2018, the Company has recorded accrued interest on the outstanding and past notes to Mr. Tomas in the amount of $375,053 and $340,009, respectively, which is included in the accrued expenses on the balance sheet. Notes payable, Dr. Comella On September 6, 2016, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and was due upon demand. During the nine months ended September 30, 2019, the Company received $107,868 of previously paid balance of the outstanding promissory note. The principal outstanding balance of this note as of September 30, 2019 and December 31, 2018 is $255,579 and $147,711, respectively. On August 7, 2017, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. The principal outstanding balance of this note as of September 30, 2019 and December 31, 2018 is $300,000. On May 7, 2018, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due six months from date of issuance. The principal outstanding balance of this note as of September 30, 2019 and December 31, 2018 is $300,000. On July 1, 2019, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due November 7, 2019. The principal outstanding balance of this note as of September 30, 2019 is $300,000. At September 30, 2019 and December 31, 2018, the Company has recorded accrued interest on the outstanding notes to Dr. Comella in the amount of $136,144 and $102,974, respectively, which is included in the accrued expenses on the balance sheet. Dr. Comella is no longer a member of the Board of Directors after September 1, 2019. Transactions with Pavillion On May 1, 2016, the Company entered into a consulting agreement with Pavillion, Inc., whose owner is related to an officer of the Company. The agreement is for 12 months and renewable for 6-month periods. Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock. For the nine months ended September 30, 2019 and 2018, the Company has incurred $0 and $90,000 of expense under the agreement, respectively. As of September 30, 2019, and December 31, 2018, the Company had $0 and $64,909, respectively, in accounts payable owed to Pavillion. On June 1, 2018, effective June 30, 2018, the Company terminated the agreement in accordance with its terms and no further compensation was derived by Pavillion. Transactions with GACP On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction, the “Asset Sale and Lease Agreement”) with GACP, whereby the Company sold certain lab, medical and other equipment relating to the cell banking business for $400,000 and leased back the sold equipment over a three year term (See “ Lab and Medical Equipment Capitalized Lease In connection with the asset sale and lease agreement, the Company is obligated to accrue 10% of banking revenue as for marketing, offset by any incurred costs of the Company. At September 30, 2019 and December 31, 2018, the outstanding accrued marketing obligation is $2,378 and $179,353, respectively (see Note 6). On March 3, 2017, the Company also entered into a customer purchase agreement with GACP, whereby the Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction. On March 3, 2017, the Company also entered into an asset purchase agreement of intellectual property with GACP whereby the Company agreed to sell all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell banking business for $50,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction. In connection with the March 3, 2017 asset purchase agreement, the CEO and CSO of U.S. Stem Cell, Inc. were also retained as CEO and CSO of American Stem Cell Centers of Excellence, which is owned by General American Capital Partners (GACP), to help with scientific and successful operational deployment of clinics. Subsequently, the CSO of U.S. Stem Cell, Inc. has vacated her position. On April 3, 2017, U.S. Stem Cell received a commitment to invest up to $5,000,000 from GACP with the intent for GACP to receive up to 63,873,275 shares of common stock. To date, GACP has invested, pursuant to this commitment, $250,000 in return for 858,281 shares. Subsequent to this investment, GACP has informed the Company that they will make no further investments pursuant to this agreement and has entered into a new agreement to open their own clinics (branded American Stem Cell) using the US Stem Cell Inc. protocols, procedures, products and technologies. As of September 30, 2019 (effective May 9, 2018), pursuant to an Amendment to Asset Sale and Lease Agreement, dated June 18, 2018, GACP has suspended their obligation to open additional clinics (tolling such obligation to a mutually agreeable date in the future) and has suspended the monthly aggregate number of stem cell kits set forth for purchase in a given month arising from such clinics. As of September 30, 2019, and December 31, 2018, GACP owns 4,021,945 shares of the Company’s common stock. As a consequence of the Court Order (see Note 10), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into the following agreements, which are not yet effective, as discussed below ● Termination and Release Agreement by and between GACP, the Company, and Michael Tomas and Kristin Comella dated September 24, 2019 (terminating the Non-Competition and Non-Solicitation Agreement between U.S. Stem Cell, Inc. and GACP Stem Cell Bank LLC., dated March 3, 2017). ● Letter Agreement on Stem Cell Processing and Storage by and between the Company and American Cell Technology, LLC The foregoing agreements are qualified in their entirety by reference to such documents, which are attached as Exhibits hereto.

NOTE 9 - STOCKHOLDERS' EQUITY

NOTE 9 - STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 — STOCKHOLDERS’ EQUITY During the nine months ended September 30, 2019, the Company issued an aggregate of 16,166,984 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred a $21,892 net gain in settlement of debt. During the nine months ended September 30, 2019, the Company issued 3,500,000 shares of its common stock for services. Stock Options On April 1, 2013, the Board of Directors approved, subject to subsequently received shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan” (replacing the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan). The 2013 Omnibus Plan initially reserved up to fifty thousand (50,000) shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand (100,000) shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of shareholders, the majority of shareholders approved the 2013 Omnibus Equity Compensation Plan. On November 2, 2015, the Board of Directors approved the increase of the reserve under the 2013 Omnibus Plan to five hundred million (500,000,000) shares of common stock for issuance, effective September 16, 2016, approved an addition of twenty five million (25,000,000) shares of common stock to the reserve, effective April 21, 2017, approved an addition of twenty five million (25,000,000) shares of common stock to the reserve, effective August 7, 2017, approved an addition of thirty million (30,000,000) shares of common stock to the reserve and effective May 7, 2018, approved an addition of one hundred million (100,000,000) shares of common stock to reserve. A summary of options at September 30, 2019 and activity during the three months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at December 31, 2018 112,970,693 $ 0.03294 8.7 Granted 33,400,000 $ 0.0057 10.0 Exercised — Forfeited/Expired (25,332,038 ) $ 0.02516 Options outstanding at September 30, 2019 121,038,655 $ 0.02663 7.2 Options exercisable at September 30, 2019 64,778,655 $ 0.02892 5.8 Available for grant at September 30, 2019 41,668,070 The following information applies to options outstanding and exercisable at September 30, 2019: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0043 13,600,000 6.05 $ 0.0043 8,050,000 $ 0.0043 0.00557 23,400,000 9.93 0.00557 - 0.00557 0.0196 21,550,000 5.34 0.0196 19,050,000 0.0196 0.02511 9,000,000 7.69 0.02511 9,000,000 0.02511 0.02576 2,220,000 8.86 0.02576 555,000 0.02576 0.03626 28,095,000 6.44 0.03626 19,985,000 0.03626 0.0536 22,500,000 7.68 0.0536 7,500,000 0.0536 0.15402 673,655 4.33 0.15402 638,655 0.15402 Total 121,038,655 6.8 $ 0.02701 64,778,655 $ 0.02964 The aggregate intrinsic value of the issued and exercisable options of $33,252 and $13,685, respectively, represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $0.006 as of September 30, 2019, which would have been received by the option holders had those option holders exercised their options as of that date. On September 1, 2019, the Company granted an aggregate 33,400,000 options to purchase the Company’s common stock at $0.00557 per share to key employees, vesting over 4 years, at grant date anniversary and exercisable over 10 years. The aggregate fair value of $192,189, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 215.10% and Risk-free rate: 1.45%. The fair value of all options vesting during the three and nine months ended September 30, 2019 of $174,450 and $512,882, respectively, was charged to current period operations. As of September 30, 2019, the Company had approximately $1,594,448 of total unrecognized compensation cost related to non-vested awards granted under the 2013 Omnibus Plan, which the Company expects to recognize over a weighted average period of 1.31 years. Warrants A summary of common stock purchase warrants at September 30, 2019 and activity during the nine months ended September 30, 2019 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at December 31, 2018 1,114,019 $ 14.735 9.1 Issued - Exercised - Expired (1,768 ) $ 532.10 Outstanding at September 30, 2019 1,112,251 $ 13.91 8.4 Exercisable at September 30, 2019 1,110,706 $ 3.24 8.4 The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2019: Warrants Outstanding Warrants Exercisable Exercise Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – 20.00 1,086,536 8.5 $ 1.267 1,086,536 $ 1.27 $ 20.01 – 30.00 19,543 4.4 $ 25.06 19,543 $ 25.06 $ 40.01 - 50.00 2,253 3.0 $ 48.83 2,253 $ 48.83 $ 50.01 –60.00 543 1.8 $ 60.00 543 $ 60.00 > $60.00 3,376 3.3 $ 3,988,74 1,831 $ 865.62 1,112,251 8.4 $ 13.91 $ 1,110,706 $ 3.24 The aggregate intrinsic value of the issued and exercisable warrants of $-0- represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $0.006 as of September 30, 2019, which would have been received by the warrant holders had those warrants holders exercised their warrants as of that date.

NOTE 10 - COMMITMENTS AND CONTI

NOTE 10 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 10 — COMMITMENTS AND CONTINGENCIES Litigation On December 12, 2017, a product liability lawsuit was filed in Broward County, specifically Jeannine Mallard v. U.S. Stem Cell, Inc., US Stem Cell Clinics LLC., Regenestem, LLC., Regenestem Network, LLC., and Kristin C. Comella. The Company will continue to defend it vigorously. On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Alejandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Alejandro Perez, ARNP, and Shareen Greenbaum, M.D. During the year ended December 31, 2016, both matters settled by the Company’s insurance policy with no additional cost to the Company, excluding the Company payment of the $100,000 insurance company deductible of which $11,000 was paid in fiscal 2017. As a result of the final settlement and determination of insurance coverage, the Company recognized $100,000 of expense due to litigation for the year ended December 31, 2017, of which $89,000 is included in accrued expenses at September 30, 2019 and December 31, 2018. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of September 30, 2019 other than that described above. Government Claim On May 9, 2018, the U.S. Department of Justice filed an injunctive action, specifically United States of America v. U.S. Stem Clinic, LLC, U.S. Stem Cell, Inc., Kristin C. Comella, and Theodore Gradel. The Complaint alleges, among other matters that the defendants manufacture “stromal vascular fraction” (SVF) products from patient adipose (fat) tissue, which the companies then market as stem cell-based treatments, and which U.S. Stem Cell Clinic, LLC administers to patients, without first obtaining what the government alleges are necessary FDA approvals. Although Theodore Gradel was initially listed as a defendant, he subsequently entered into a consent agreement and is no longer party to this case. The U.S. and the defendants filed cross motions for summary judgment, each asking for a ruling in its favor. On June 3, 2019, the Court entered an order granting Summary Judgment for the government and denying the defendants’ motion for summary judgment. The order focused on the defendants’ actions in providing and marketing SVF therapy. In an order dated June 4, 2019, the Court granted the defendants’ request to allow it the opportunity to work out the language of the form of injunction with the government, and if unsuccessful, to provide a status report to the Court by June 14, 2019, outlining areas of disagreement. The Court further ordered that the defendants (U.S. Stem Clinic, LLC, U.S. Stem Cell, Inc., and Kristin C. Comella) ‘not sell, provide or otherwise engage in any SVF therapy or any other activities to be regulated by the FDA as explained in the Court’s Order on the Parties’ Motions for Summary Judgment.” On June 25, 2019, the Court entered an Order of Permanent Injunction, generally enjoining the defendants with respect to the SVF Product and requiring other actions. On – August 23, 2019, the Company has filed a notice of appeal of this judgment, and orders entered subsequent to the judgment. In the interim, the Company has complied with the injunction requirements of the Court. The Company, in divesting certain equipment and other assets and assigning its lease, has and will continue to experience a decrease in revenues as the Company both maintains the remainder of the business and transitions into similar or unrelated business opportunities as determined by management (see Item 2 Existing Capital Resources and Future Capital Requirements and Plan of Operations ) Since the Court’s issuance of the Order of Permanent Injunction, the Company has received demand letters for compensation from persons who store their SVF Product and/or other tissue product with the tissue bank (several of the persons have requested refunds of the monies paid to the tissue bank and one person has requested a full refund of monies paid to an altogether separate company due to her not receiving the full amount of treatments she requested; such requests for compensation, to date, have not been material) and requests that the Company preserve cells in the Company’s possession. The Company sought guidance from the Court, which entered an order generally staying the requirement to destroy any SVF Product, pending a decision on the Company’s appeal. Settlement Agreement and General Release The Company was one of the parties to a Settlement Agreement and General Release (the “Agreement”) dated June 3, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% Promissory Note, dated June 15, 2019, in the principal amount of Five Hundred Thousand Dollars ($500,000), payable in monthly increments of Five Thousand ($5,000) per month (see Note 7, Weider Promissory Note, )

NOTE 11 - FAIR VALUE MEASUREMEN

NOTE 11 - FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 11 — FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of September 30, 2019, and December 31, 2018, the Company did not have any items that would be classified as level 1 or 2 disclosures. As of September 30, 2019, and December 31, 2018, the Company did not have any derivative instruments that were designated as hedges. There were no derivative and warrant liability as of September 30, 2019 and December 31, 2018.

NOTE 12 - SUBSEQUENT EVENTS

NOTE 12 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 — SUBSEQUENT EVENTS After September 30, 2019, the Company address has changed to 1560 Sawgrass Corporate Pkwy 4th Floor, Sunrise, FL 33323 with a month to month lease at a cost of On October 15, 2019, the Company, as a result of being unable to meet the $0.01 bid test, is no longer being quoted on “The OTCQB® Venture Market” but is being reported on the “pink sheets” under the symbol “USRM.PK.” As a consequence of the Court Order (see Note 10), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into an Assignment and Assumption of Lease by and between the Company, American Cell Technology, LLC, and Sawgrass Business Plaza, LLC, dated October 24, 2019. In October 2019, the Company issued 1,692,353 shares of common stock as payment of $9,195.12 Northstar interest. In October 2019, the Company issued an aggregate of 5,011,747 shares of common stock for services rendered. In October 2019, the Company issued an aggregate of 2,661,935 shares of common stock for investment.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the sector of the cell technology industry delivering cell therapies and biologics that help address a variety of injuries and diseases such as osteoarthritis, heart failure, lower limb ischemia, neurological conditions, autoimmune diseases and other issues. The primary business includes the development of proprietary cell therapy procedure and products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, revenues realized from an Asset Sale and Lease Agreement related to the segment of the Company business involving collecting, growing and banking cell cultures and treatment kits for humans and animals), and the operation of a cell therapy clinic (subsequently limited by the Order of Permanent Injunction, see below ). To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. In addition, the recent Order of Permanent Injunction arising from the action brought by the Department of Justice (see Note 11), has resulting in management considering modifications to the Company business model in order to offset the loss of revenue resulting from the consequences of this Injunctive Order. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.
Revenue [Policy Text Block]	Revenue Recognition Effective January 1, 2018, the Company recognizes revenue in accordance with Accounting Standards Codification 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from in-person trainings are recognized when the training occurs and revenues from on demand online trainings are recognized when the customer purchases the rights to the training course. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as multiple performance obligations as described in ASC 606 and addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on stand-alone pricing. The multiple performance obligations include stem cell banking, dose retrieval and yearly storage fees. Revenues for stem cell banking and dose retrieval is recognized at the point of service and revenues for the yearly storage fees is recognized over the term of the banking contract, which is typically one year with annual renewals. Revenues have been adversely impacted by the Order of Permanent Injunction (see the Notes herein including Note 10). At September 30, 2019 and December 31, 2018, the Company had deferred revenues of $246,775 and $293,665, respectively, which includes $63,250 and $68,500, respectively, to the Intellectual Property Licensing Agreement.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Receivable [Policy Text Block]	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2019, and December 31, 2018, allowance for doubtful accounts was $13,203 and $30,808, respectively.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Equity Method Investments [Policy Text Block]	Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 49.9 percent member interest ownerships of U.S. Stem Cell Clinic, LLC and Regenerative Wellness Clinic, LLC respectively and its 49 percent member interest ownership of U.S. Stem Cell Clinic of the Villages utilizing the equity method of accounting (See Note 3).
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years. Equipment under capital leases are recorded at the estimated present value of the minimum lease payments. Equipment under capital leases are amortized over the term of the lease, which is three years.
Share-based Payment Arrangement [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2019 and 2018 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2019 September 30, 2018 Options to purchase common stock 121,038,655 103,970,693 Warrants to purchase common stock 1,112,251 1,118,019 Totals 122,150,906 105,088,712
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2019, two customers represented 55% and 21%, respectively, representing an aggregate of 76% of the Company’s accounts receivable. As of December 31, 2018, four customers represented 41%, 10%, 16% and 10% respectively, representing an aggregate of 77% of the Company’s accounts receivable. For the three months ended September 30, 2019, the Company’s revenues earned from sale of products and services were $156,591, of which three customers, one a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 49.9% interest) represented 27%, 21% and 11% (related party). For the three months ended September 30, 2018, the Company’s revenues earned from sale of products and services were $1,503,884, of which two customers represented 12% and 10%, respectively, one of which is a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 49% interest) represented 12% of Company’s revenue. For the nine months ended September 30, 2019, the Company’s revenues earned from sale of products and services were $2,763,385, of which one customer represented, a related party, (US Stem Cell Clinic LLC, a partly owned investment in with the Company holds a 49.9% interest), represents 12% of Company’s revenue. For the nine months ended September 30, 2018, the Company’s revenues earned from sale of products and services were $5,037,242, of which two customers represented 11% and 8% respectively, of Company’s revenue, one of which is a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company held a 49.9% interest) represented 11%.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $0 and $263 for the three and nine months ended September 30, 2019, respectively; and $599 and $4,527 for the three and nine months ended September 30, 2018, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Deposit Contracts, Policy [Policy Text Block]	Deposits Deposits are comprised of the following: On March 3, 2017, the Company entered into a customer purchase agreement with General American Capital Partners (GACP), whereby the Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 8). On March 3, 2017, the Company entered into an asset purchase agreement of intellectual property with GACP whereby the Company agreed to sell all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell banking business for $50,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 8). As a consequence of the Court Order (see Note 10), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into a Termination and Release Agreement and a Letter Agreement intended to divested itself of certain equipment and other assets underlying the related equipment lease transaction (see Notes, 4, and 8).
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Accounting Standards In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new ROU assets and lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, the Company recognized additional operating lease liabilities, net of deferred rent, of approximately $57,000 based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $57,000. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Beginning in 2019, the Company changed to its disclosed lease recognition policies and practices, as well as to other related financial statement disclosures due to the adoption of this standard. See Note 5. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 1 - SIGNIFICANT ACCOUNTI_2

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2019 September 30, 2018 Options to purchase common stock 121,038,655 103,970,693 Warrants to purchase common stock 1,112,251 1,118,019 Totals 122,150,906 105,088,712

NOTE 4 - PROPERTY AND EQUIPME_2

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2019 and December 31, 2018 is summarized as follows: September 30, 2019 December 31, 2018 Laboratory and medical equipment $ 5,590 $ 5,590 Furniture, fixtures and equipment 125,633 125,633 Computer equipment 49,951 49,951 Equipment under capital lease 624,602 624,602 Leasehold improvements 362,046 362,046 1,167,822 1,167,822 Less accumulated depreciation and amortization (1,080,163 ) (925,207 ) $ 87,659 $ 242,615

NOTE 5 - RIGHT TO USE ASSETS _2

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	Right to use assets is summarized below: September 30, 2019 Sunrise Facility $ 383,351 Less accumulated depreciation (7,758 ) Right to use assets, net $ 375,593 September 30, 2019 Sunrise, FL $ 376,045 Less: short term portion (59,970 ) Long term portion $ 316,075
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity analysis under these lease agreements are as follows: Three months ended December 31, 2019 $ 21,919 Year ended December 31, 2020 88,551 Year ended December 31, 2021 91,208 Year ended December 31, 2022 93,944 Year ended December 31, 2023 96,762 Year ended December 31, 2024 65,786 458,170 Less: Present value discount (82,125 ) Lease liability $ 376,045
Lease, Cost [Table Text Block]	Operating lease expense $ 34,560 Variable lease expense - $ 34,560 Operating lease expense $ 105,200 Variable lease expense 685 $ 105,885

NOTE 6 - ACCRUED EXPENSES (Tabl

NOTE 6 - ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank $ 422,934 $ 347,235 Interest payable on notes payable-related party (See Note 8) 555,571 482,784 Vendor accruals and other 146,420 146,420 Payroll and related expenses 14,837 - Marketing obligation 2,378 179,353 $ 1,142,140 $ 1,155,792

NOTE 7 - NOTES AND CAPITAL LE_2

NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes and capital lease payable were comprised of the following as of September 30, 2019 and December 31, 2018: September 30, 2019 December 31, 2018 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams note(s) payable 394,500 444,000 Weider promissory note payable 491,525 - Power Up Lending Group notes payable 40,838 145,476 Lab and medical equipment capitalized leases 97,892 264,590 Total notes payable 2,004,785 1,834,076 Less unamortized debt discount (36,032 ) (74,653 ) Total notes payable net of unamortized debt discount 1,968,753 1,759,423 Less current portion (1,512,227 ) (462,330 ) Long term portion $ 456,496 $ 1,297,093
Schedule of Capital Leased Assets [Table Text Block]	The following summarizes the assets under capital leases: September 30, 2019 December 31, 2018 Classes of property Lab, medical and other equipment $ 619,825 $ 619,825 Office equipment 4,777 4,777 Less: accumulated depreciation (538,515 ) (383,559 ) $ 86,087 $ 241,043 September 30, 2019 December 31, 2018 Current leases payable $ 97,892 $ 225,084 Long-term leases payable - 39,506 Total $ 97,892 $ 264,590
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The following summarizes total future minimum lease payments at September 30, 2019: Period ending, Three months ended December 31, 2019 60,000 Year ended December 31, 2020 40,000 Total minimum lease payments 100,000 Amount representing interest (2,108 ) Present value of minimum lease payments 97,892 Current portion of capital lease obligations 97,892 Capital lease obligation, less current portion $ -

NOTE 8 - RELATED PARTY TRANSA_2

NOTE 8 - RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Officer and Director Notes September 30, 2019 December 31, 2018 Note payable, Mr. Tomas $ 161,786 $ 483,393 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Dr. Comella* 255,579 147,711 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 - Total $ 2,317,365 $ 1,731,104 * Dr. Comella is no longer a member of the Board of Directors after September 1, 2019.

NOTE 9 - STOCKHOLDERS' EQUITY (

NOTE 9 - STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of options at September 30, 2019 and activity during the three months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at December 31, 2018 112,970,693 $ 0.03294 8.7 Granted 33,400,000 $ 0.0057 10.0 Exercised — Forfeited/Expired (25,332,038 ) $ 0.02516 Options outstanding at September 30, 2019 121,038,655 $ 0.02663 7.2 Options exercisable at September 30, 2019 64,778,655 $ 0.02892 5.8 Available for grant at September 30, 2019 41,668,070
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The following information applies to options outstanding and exercisable at September 30, 2019: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0043 13,600,000 6.05 $ 0.0043 8,050,000 $ 0.0043 0.00557 23,400,000 9.93 0.00557 - 0.00557 0.0196 21,550,000 5.34 0.0196 19,050,000 0.0196 0.02511 9,000,000 7.69 0.02511 9,000,000 0.02511 0.02576 2,220,000 8.86 0.02576 555,000 0.02576 0.03626 28,095,000 6.44 0.03626 19,985,000 0.03626 0.0536 22,500,000 7.68 0.0536 7,500,000 0.0536 0.15402 673,655 4.33 0.15402 638,655 0.15402 Total 121,038,655 6.8 $ 0.02701 64,778,655 $ 0.02964
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of common stock purchase warrants at September 30, 2019 and activity during the nine months ended September 30, 2019 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at December 31, 2018 1,114,019 $ 14.735 9.1 Issued - Exercised - Expired (1,768 ) $ 532.10 Outstanding at September 30, 2019 1,112,251 $ 13.91 8.4 Exercisable at September 30, 2019 1,110,706 $ 3.24 8.4
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2019: Warrants Outstanding Warrants Exercisable Exercise Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – 20.00 1,086,536 8.5 $ 1.267 1,086,536 $ 1.27 $ 20.01 – 30.00 19,543 4.4 $ 25.06 19,543 $ 25.06 $ 40.01 - 50.00 2,253 3.0 $ 48.83 2,253 $ 48.83 $ 50.01 –60.00 543 1.8 $ 60.00 543 $ 60.00 > $60.00 3,376 3.3 $ 3,988,74 1,831 $ 865.62 1,112,251 8.4 $ 13.91 $ 1,110,706 $ 3.24

NOTE 1 - SIGNIFICANT ACCOUNTI_3

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Mar. 03, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jan. 01, 2019	Jan. 30, 2018
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Deferred Revenue (in Dollars)		$ 246,775		$ 246,775		$ 293,665
Accounts Receivable, Allowance for Credit Loss, Current (in Dollars)		13,203		13,203		30,808
Revenues (in Dollars)		156,591	$ 1,503,884	2,763,385	$ 5,037,242
Research and Development Expense (in Dollars)		0	$ 599	263	4,527
Proceeds from Sale of Machinery and Equipment (in Dollars)	$ 50,000
Operating Lease, Liability (in Dollars)		376,045		376,045			$ 57,000
Operating Lease, Right-of-Use Asset (in Dollars)		375,593		$ 375,593		$ 0	$ 57,000
Minimum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life				3 years
Maximum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life				15 years
Credit Concentration Risk [Member] | Accounts Receivable [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage						77.00%
Customer Concentration Risk [Member] | Revenue from Contract with Customer, Product and Service Benchmark [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			49.00%	12.00%
Revenues (in Dollars)		156,591	$ 1,503,884	$ 2,763,385	5,037,242
Royalty Arrangement [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Deferred Revenue (in Dollars)		$ 63,250		$ 63,250		$ 68,500
Assets Held under Capital Leases [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life				3 years
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage		49.90%		49.90%		33.30%
Revenues (in Dollars)		$ 33,614	183,832	$ 329,003	529,880
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage		49.00%		49.00%				49.00%
Revenues (in Dollars)		$ 9,975	$ 64,074	$ 140,328	$ 143,550
Customer One [Member] | Credit Concentration Risk [Member] | Accounts Receivable [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				55.00%		41.00%
Customer One [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer, Product and Service Benchmark [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		27.00%	12.00%		11.00%
Customer Two [Member] | Credit Concentration Risk [Member] | Accounts Receivable [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				21.00%		10.00%
Customer Two [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer, Product and Service Benchmark [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		21.00%	10.00%		8.00%
Customer Three [Member] | Credit Concentration Risk [Member] | Accounts Receivable [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage				76.00%		16.00%
Customer Three [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer, Product and Service Benchmark [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		11.00%	12.00%
Customer Four [Member] | Credit Concentration Risk [Member] | Accounts Receivable [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage						10.00%

NOTE 1 - SIGNIFICANT ACCOUNTI_4

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	122,150,906	105,088,712
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	121,038,655	103,970,693
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,112,251	1,118,019

NOTE 2 - GOING CONCERN AND MA_2

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (1,645,949)	$ (839,126)	$ (673,218)	$ (330,937)	$ (1,244,534)	$ (139,159)	$ (3,158,293)	$ (1,714,630)
Working Capital (Deficit)	$ (8,751,403)						$ (8,751,403)

NOTE 3 - INVESTMENTS (Details)

NOTE 3 - INVESTMENTS (Details) - USD ($)	Jan. 30, 2018	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Sep. 30, 2019
U.S. Stem Cell Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage			49.90%		49.90%		33.30%			49.90%
Income (Loss) from Equity Method Investments			$ (20,637)	$ 82,950	$ 51,514	$ 171,740				$ 599,721
Proceeds from Equity Method Investment, Distribution					64,870	154,000
Proceeds from Equity Method Investment, Distribution, Return of Capital										663,870
Investments			0		0		$ 8,921			0
Accounts Receivable, after Allowance for Credit Loss			0		0		$ 9			$ 0
Revenues			$ 33,614	183,832	$ 329,003	529,880
Investment Company, Contributed Capital, Percent		16.60%
Contribution to Equity		$ 4,435
Regenerative Wellness Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage			49.90%		49.90%		33.30%			49.90%
Income (Loss) from Equity Method Investments			$ (2,910)	58,931	$ 69,345	73,247		$ (9,695)	$ 113,047
Proceeds from Equity Method Investment, Distribution					101,963	21,000			101,963
Accounts Receivable, after Allowance for Credit Loss			0		0		$ 0			$ 0
Revenues			$ 16,637	64,945	$ 132,984	149,469
Investment Company, Contributed Capital, Percent		16.60%
Contribution to Equity		$ 10,830
Equity Method Investments							21,787		$ 0
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.00%		49.00%		49.00%					49.00%
Income (Loss) from Equity Method Investments			$ (9,931)	18,335	$ (27,081)	18,335
Proceeds from Equity Method Investment, Distribution							63,700
Revenues			9,975	$ 64,074	140,328	$ 143,550
Equity Method Investments			0		0		27,081			$ 0
Related Party Transaction, Description of Transaction	To that end, U.S. Stem Cell Clinic of The Villages LLC (the “LLC”) was formed on January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the LLC.  Currently, Knutson holds a 51%-member interest in the LLC and the Company holds a 49%-member interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the LLC gross revenues
Ownership Percentage by Knutson	51.00%
Proceeds from Contributed Capital							86,750
Accounts Receivable, before Allowance for Credit Loss							$ 0
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member] | Utilized for Fromation of LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Related Party Transaction, Amounts of Transaction	$ 300,000
Management Fees-related Party [Member] | U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Revenues			$ 975		$ 50,751

NOTE 4 - PROPERTY AND EQUIPME_3

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 03, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Sale Leaseback Transaction, Net Book Value	$ 400,000
Sale Leaseback Transaction, Lease Terms	leased back the sold equipment over a three-year term
Capital Leased Assets, Gross		$ 624,602		$ 624,602		$ 624,602
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation		538,515		538,515		383,559
Sale Leaseback Transaction, Deferred Gain, Gross	$ 386,535
Sale Leaseback Transaction, Current Period Gain Recognized		32,211	$ 32,211	96,634	$ 96,634
Sale Leaseback Transaction, Deferred Gain, Net		53,686		53,686		150,319
Depreciation		51,652	51,652	154,956	154,956
Cost, Depreciation		51,652	$ 51,652	155,480	$ 154,956
Assets Held under Capital Leases [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Capital Leased Assets, Gross		624,602		624,602		624,602
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation		$ 533,738		$ 533,738		$ 383,559

NOTE 4 - PROPERTY AND EQUIPME_4

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Schedule of Property and Equipment [Abstract]
Laboratory and medical equipment	$ 5,590	$ 5,590
Furniture, fixtures and equipment	125,633	125,633
Computer equipment	49,951	49,951
Equipment under capital lease	624,602	624,602
Leasehold improvements	362,046	362,046
	1,167,822	1,167,822
Less accumulated depreciation and amortization	(1,080,163)	(925,207)
	$ 87,659	$ 242,615

NOTE 5 - RIGHT TO USE ASSETS _3

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details)	Sep. 01, 2019USD ($)	Sep. 30, 2019USD ($)ft²	Sep. 30, 2019USD ($)ft²	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Estimated Incremental Borrowing Rate			8.00%
Operating Lease, Liability		$ 376,045	$ 376,045	$ 57,000
Operating Lease, Right-of-Use Asset		375,593	375,593	57,000	$ 0
Lease, Cost		$ 34,560	$ 105,885
Sunrise, Florida [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Area of Land (in Square Feet) | ft²		4,860	4,860
Operating Leases, Annual Rent Amount	$ 87,674		$ 82,620
Operating Leases, Monthly Base Rent Amount			7,306
Estimated Incremental Borrowing Rate	8.00%
Operating Lease, Liability	$ 383,351
undefined		$ 383,351	383,351	274,180
Operating Lease, Right-of-Use Asset		375,593	375,593
Lease, Cost		$ 34,560	$ 105,885
Lease Escalation [Member] | Sunrise, Florida [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Leases, Annual Rent Amount	$ 98,678
Accounting Standards Update 2016-02 [Member] | Sunrise, Florida [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Liability				56,734
Operating Lease, Right-of-Use Asset				$ 56,734

NOTE 5 - RIGHT TO USE ASSETS _4

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Summary of Right to Use Assets and Lease Liability - USD ($)	Sep. 30, 2019	Sep. 01, 2019	Jan. 01, 2019	Dec. 31, 2018
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Summary of Right to Use Assets and Lease Liability [Line Items]
Right to use assets, net	$ 375,593		$ 57,000	$ 0
Sunrise, FL	376,045		57,000
Less: short term portion	(59,970)			0
Long term portion	316,075			$ 0
Sunrise, Florida [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Summary of Right to Use Assets and Lease Liability [Line Items]
Facility under lease	383,351		$ 274,180
Less accumulated depreciation	(7,758)
Right to use assets, net	375,593
Sunrise, FL		$ 383,351
Los Angeles, Suite 740 [Member]
NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Summary of Right to Use Assets and Lease Liability [Line Items]
Less: short term portion	(59,970)
Long term portion	$ 316,075

NOTE 5 - RIGHT TO USE ASSETS _5

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Maturity Analysis Under Lease Agreements - USD ($)	Sep. 30, 2019	Jan. 01, 2019
Maturity Analysis Under Lease Agreements [Abstract]
Three months ended December 31, 2019	$ 21,919
Year ended December 31, 2020	88,551
Year ended December 31, 2021	91,208
Year ended December 31, 2022	93,944
Year ended December 31, 2023	96,762
Year ended December 31, 2024	65,786
	458,170
Less: Present value discount	(82,125)
Lease liability	$ 376,045	$ 57,000

NOTE 5 - RIGHT TO USE ASSETS _6

NOTE 5 - RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Disclosure of Lease Expense - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Disclosure of Lease Expense [Abstract]
Operating lease expense	$ 34,560	$ 105,200
Variable lease expense	0	685
	$ 34,560	$ 105,885

NOTE 6 - ACCRUED EXPENSES (Deta

NOTE 6 - ACCRUED EXPENSES (Details) - Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	9 Months Ended
	Sep. 30, 2019USD ($)shares
NOTE 6 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares	16,166,984
Gain (Loss) on Extinguishment of Debt | $	$ (23,168)

NOTE 6 - ACCRUED EXPENSES (De_2

NOTE 6 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Schedule of Accrued Liabilities [Abstract]
Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank	$ 422,934	$ 347,235
Interest payable on notes payable-related party (See Note 8)	555,571	482,784
Vendor accruals and other	146,420	146,420
Payroll and related expenses	14,837	0
Marketing obligation	2,378	179,353
	$ 1,142,140	$ 1,155,792

NOTE 7 - NOTES AND CAPITAL LE_3

NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details)	Jun. 15, 2019USD ($)	Apr. 16, 2019USD ($)	Nov. 08, 2018USD ($)	Aug. 31, 2017USD ($)	Mar. 03, 2017USD ($)	Jun. 01, 2015USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Mar. 31, 2018	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2018USD ($)	Oct. 25, 2010
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.25%
Notes Payable								$ 2,004,785			$ 2,004,785			$ 1,834,076
Debt Instrument, Unamortized Discount								36,032			36,032			74,653
Amortization of Debt Discount (Premium)											141,296	$ 164,312
Debt Instrument, Face Amount	$ 500,000
Debt Instrument, Periodic Payment	$ 5,000
Gain (Loss) on Extinguishment of Debt								33,203	$ 80,200		21,892	45,013
Capital Lease Obligations								97,892			97,892			264,590
Power Up Lending Group Notes Payable [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable								40,838			40,838			145,486
Debt Instrument, Unamortized Discount								36,032			36,032			43,452
Notes Payable to Banks [Member] | Seaside National Bank and Trust [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage															4.25%
Debt Instrument, Maturity Date										May 18, 2020
Notes Payable								980,000			980,000			980,000
Notes Payable, Other Payables [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount														99,183
Notes Payable, Other Payables [Member] | Hunton & Williams Notes [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													8.00%
Number of Outstanding Notes Payable													2
Notes Payable								394,500			394,500			444,000
Debt Instrument, Payment Terms				payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring									payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar Biotech Group, LLC (or successor) Loan is paid off.
Other Notes Payable				$ 747,680
Accounts Payable, Other, Current				40,596
Notes and Loans Payable				$ 788,276
Debt Instrument, Description				The note holder agreed to accept full payment of their obligation of over a four (4) year period in 48 monthly installments on an adjusted debt obligation in aggregate of $624,000 (reducing the outstanding balance), with such payments staggered in amounts such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year.  In addition, the note holder agreed to suspend accrual interest on the notes commencing September 1, 2017.
Imputed Interest, Rate				5.00%
Debt Instrument, Unamortized Discount				$ 69,700
Amortization of Debt Discount (Premium)								24,205	6,343		34,945	22,426
Notes Payable, Other Payables [Member] | Hunton & Williams Note #1 [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable													$ 61,150
Notes Payable, Other Payables [Member] | Hunton & Williams Note #2 [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable													$ 323,822
Notes Payable, Other Payables [Member] | Weider promissory note [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.25%
Notes Payable								491,525			491,525			0
Debt Instrument, Face Amount	$ 500,000
Debt Instrument, Periodic Payment	$ 5,000
Notes Payable, Other Payables [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable								40,838			40,838			145,476
Notes Payable, Other Payables [Member] | Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Maturity Date						Jun. 1, 2020
Notes Payable								1,397,762			1,397,762
Imputed Interest, Rate						5.00%
Debt Instrument, Unamortized Discount						$ 368,615		46,911			46,911
Amortization of Debt Discount (Premium)								17,616	$ 17,616		52,273	$ 52,273
Debt Instrument, Face Amount						1,697,762
Debt Instrument, Periodic Payment						$ 75,000
Debt Instrument, Interest Rate Terms						non-interest bearing
Debt Instrument, Frequency of Periodic Payment						four semi-annual
Debt Instrument, Date of First Required Payment						Dec. 31, 2015
Capital Lease Obligations [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable								$ 97,892			97,892			$ 264,590
Debt Instrument, Face Amount					$ 400,000
Debt Instrument, Term					3 years
Capital Lease Obligations					$ 619,825
Sale Leaseback Transaction, Monthly Rental Payments					$ 20,000
Principal [Member] | Notes Payable, Other Payables [Member] | Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount						$ 1,500,000
Interest [Member] | Notes Payable, Other Payables [Member] | Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount						373,469
Unpaid Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount						$ 624,737
Revenue Based Factoring Agreement [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Payment Terms		Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,276 for 147 business days.	Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,276 for 147 business days
Debt Instrument, Face Amount		$ 187,600	$ 187,600
Proceeds from Issuance of Debt		137,200	137,200
Debt Instrument, Fee Amount		2,800	2,800
Proceeds from Debt, Net of Issuance Costs		$ 84,876	93,809
Gain (Loss) on Extinguishment of Debt			$ (37,604)								$ (1,276)
Subsequent Event [Member] | Notes Payable, Other Payables [Member] | Hunton & Williams Notes [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Repayments of Debt							$ 5,000
Revenue Precentage, Year One [Member] | Capital Lease Obligations [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Sale Leaseback Transaction, Rate of Revenues to be Paid					2.30%
Revenue Precentage, Year Two [Member] | Capital Lease Obligations [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Sale Leaseback Transaction, Rate of Revenues to be Paid					22.50%
Revenue Precentage, Year Three [Member] | Capital Lease Obligations [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Sale Leaseback Transaction, Rate of Revenues to be Paid					31.60%

NOTE 7 - NOTES AND CAPITAL LE_4

NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Aug. 31, 2017
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 2,004,785	$ 1,834,076
Less unamortized debt discount	(36,032)	(74,653)
Total notes payable net of unamortized debt discount	1,968,753	1,759,423
Less current portion	(1,512,227)	(462,330)
Long term portion	456,496	1,297,093
Power Up Lending Group Notes Payable [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	40,838	145,486
Less unamortized debt discount	(36,032)	(43,452)
Notes Payable to Banks [Member] | Seaside National Bank and Trust [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	980,000	980,000
Notes Payable, Other Payables [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Less unamortized debt discount		(99,183)
Notes Payable, Other Payables [Member] | Hunton & Williams Notes [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	394,500	444,000
Less unamortized debt discount			$ (69,700)
Notes Payable, Other Payables [Member] | Weider promissory note [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	491,525	0
Notes Payable, Other Payables [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	40,838	145,476
Capital Lease Obligations [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 97,892	$ 264,590

NOTE 7 - NOTES AND CAPITAL LE_5

NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Capital Leased Assets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Capital Leased Assets [Line Items]
Capital Leased Assets, Gross	$ 624,602	$ 624,602
Less: accumulated depreciation	(538,515)	(383,559)
Capital Leases, Balance Sheet, Assets by Major Class, Net	86,087	241,043
Current leases payable	97,892	225,084
Long-term leases payable	0	39,506
Total	97,892	264,590
Equipment [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Capital Leased Assets [Line Items]
Capital Leased Assets, Gross	619,825	619,825
Office Equipment [Member]
NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Capital Leased Assets [Line Items]
Capital Leased Assets, Gross	$ 4,777	$ 4,777

NOTE 7 - NOTES AND CAPITAL LE_6

NOTE 7 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Future Minimum Lease Payments for Capital Leases - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Period ending,
Three months ended December 31, 2019	$ 60,000
Year ended December 31, 2020	40,000
Total minimum lease payments	100,000
Amount representing interest	(2,108)
Present value of minimum lease payments	97,892
Current portion of capital lease obligations	97,892	$ 225,084
Capital lease obligation, less current portion	$ 0	$ 39,506

NOTE 8 - RELATED PARTY TRANSA_3

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($)		Jul. 01, 2019	Oct. 19, 2018	May 07, 2018	Apr. 19, 2018	Oct. 02, 2017	Aug. 07, 2017	Apr. 03, 2017	Apr. 01, 2017	Mar. 09, 2017	Mar. 03, 2017	Mar. 01, 2017	Oct. 06, 2016	May 01, 2016	Apr. 07, 2016	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2013	Jun. 15, 2019	Dec. 31, 2018	Sep. 06, 2016	Dec. 31, 2015	Feb. 28, 2013	Feb. 29, 2012
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current																										$ 374,901						$ 374,901				$ 234,901
Debt Instrument, Face Amount																																			$ 500,000
Class of Warrant or Rights, Granted (in Shares)																																0
Debt Instrument, Interest Rate, Stated Percentage																																			5.25%
Preferred Stock, Shares Authorized (in Shares)																										20,000,000						20,000,000				20,000,000		20,000,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)												20,000,000				34,522
Stock Issued During Period, Value, Other																										$ 34,013	$ 89,220	$ 188,961	$ 53,889	$ 204,497	$ 147,713
Debt Conversion, Original Debt, Amount																$ 100,000
Notes Payable, Related Parties																										2,317,365						$ 2,317,365				$ 1,731,104
Repayments of Notes Payable																																381,000	$ 484,381
Repayments of Related Party Debt																																213,739	542,971
Accounts Payable, Related Parties, Current																										3,167						3,167				75,714
Sale Leaseback Transaction, Net Book Value											$ 400,000
Sale Leaseback Transaction, Lease Terms											leased back the sold equipment over a three-year term
Percentage of Renenue Accrued for Marketing											10.00%
Accrued Marketing Costs, Current																										$ 2,378						$ 2,378				$ 179,353
Sale Leaseback Transaction, Description											Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer.  There is no reduction in the selling price should the new customers be fewer than 5,000.  The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction
Proceeds from Sale of Machinery and Equipment											$ 50,000
Northstar Claims [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Percentage of Revenues to be Received as Royalty												10.00%
Stockholders' Equity, Other Shares (in Shares)												11,000,000
Number of Directors												2
Equity Method Investment, Ownership Percentage												5.00%
Northstar Claims [Member] | Stock Issued for Conversion of Series A Preferred Stock and Litigation Case [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)									1,000,000	30,000,000
GACP Stem Cell Bank, LLC [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Investment Agreement, Value								$ 5,000,000
Investment Agreement, Number of Shares (in Shares)								63,873,275
Proceeds from Issuance or Sale of Equity								$ 250,000
Stock Issued During Period, Shares, New Issues (in Shares)								858,281
Shares Held by Affiliate (in Shares)																										4,021,945						4,021,945				4,021,945
Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Description of Transaction														The agreement is for 12 months and renewable for 6-month periods.  Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock
Professional Fees																																$ 0	$ 90,000
Accounts Payable, Related Parties, Current																										$ 0						0				$ 64,909
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																								$ 544,267
Debt Instrument, Payment Terms																							Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)																								5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default																							entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
Percentage of Revenues to be Received as Royalty																							8.00%
Debt Instrument, Interest Rate, Stated Percentage																							12.85%																7.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			164,523		379,141	559,187			286,315												3,916	8,772
Debt Conversion, Original Debt, Amount			$ 9,195		$ 9,145	$ 12,705			$ 12,703												$ 85,447	$ 100,000
Notes Payable, Related Parties																										262,000						262,000				262,000
Affiliated Entity [Member] | Interest [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)													848,490		57,778		4,156	1,363	515	275
Debt Conversion, Original Debt, Amount													$ 12,705				$ 12,705	$ 12,635	$ 12,705	$ 12,635
Debt Conversion, Converted Instrument, Amount															$ 12,705
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																										375,053						375,053				340,009
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #5 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount							$ 500,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Notes Payable, Related Parties																										161,786						161,786				483,393
Debt Instrument, Term							1 year
Repayments of Notes Payable																																321,607
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #6 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount				$ 500,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Notes Payable, Related Parties																										500,000	$ 500,000					500,000				500,000
Debt Instrument, Term				6 months
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #7 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount		$ 500,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Notes Payable, Related Parties																										500,000						500,000				0
Debt Instrument, Maturity Date		Nov. 7, 2019
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																										136,144						136,144				102,974
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #5 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount		$ 300,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Notes Payable, Related Parties	[1]																									300,000						300,000				0
Debt Instrument, Maturity Date		Nov. 7, 2019
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #2 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																					$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																																					5.00%
Notes Payable, Related Parties	[1]																									255,579						255,579				147,711
Repayments of Related Party Debt																																107,868
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #3 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Notes Payable, Related Parties	[1]																									300,000						300,000				300,000
Debt Instrument, Term							1 year
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #4 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount				$ 300,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Notes Payable, Related Parties	[1]																									$ 300,000						$ 300,000				$ 300,000
Debt Instrument, Term				6 months
Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights																							modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock
Series A Preferred Stock [Member] | Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Value, Other																																		$ 316,800
[1]	Dr. Comella is no longer a member of the Board of Directors after September 1, 2019.

NOTE 8 - RELATED PARTY TRANSA_4

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Notes Payable - USD ($)		Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Notes Payable, Related Party		$ 2,317,365		$ 1,731,104
Notes Payable, Other Payables [Member] | Note Payable #5 [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		161,786		483,393
Notes Payable, Other Payables [Member] | Note Payable #5 [Member] | Chief Scientific Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	300,000		0
Notes Payable, Other Payables [Member] | Note Payable #6 [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		500,000	$ 500,000	500,000
Notes Payable, Other Payables [Member] | Note Payable #7 [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		500,000		0
Notes Payable, Other Payables [Member] | Note Payable #2 [Member] | Chief Scientific Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	255,579		147,711
Notes Payable, Other Payables [Member] | Note Payable #3 [Member] | Chief Scientific Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	300,000		300,000
Notes Payable, Other Payables [Member] | Note Payable #4 [Member] | Chief Scientific Officer [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	$ 300,000		$ 300,000
[1]	Dr. Comella is no longer a member of the Board of Directors after September 1, 2019.

NOTE 9 - STOCKHOLDERS' EQUITY_2

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - USD ($)	Sep. 01, 2019	May 07, 2018	Aug. 07, 2017	Apr. 21, 2017	Sep. 16, 2016	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt (in Dollars)						$ 33,203	$ 80,200	$ 21,892	$ 45,013
Stock Issued During Period, Shares, Issued for Services								3,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)						33,252		$ 33,252
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)						$ 13,685		$ 13,685
Share Price (in Dollars per share)						$ 0.006		$ 0.006
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	33,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price (in Dollars per share)	$ 0.00557
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Fair Value of Options (in Dollars)	$ 192,189
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	215.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.45%
Share-based Payment Arrangement, Noncash Expense (in Dollars)								$ 586,382	$ 812,300
Aggregate Intrinsic Value of the Issued and Exercisable Warrants (in Dollars)								0.006
Share-based Payment Arrangement, Option [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Share-based Payment Arrangement, Noncash Expense (in Dollars)						$ 174,450		512,882
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars)						$ 1,594,448		$ 1,594,448
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition								1 year 113 days
Accounts Payable [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Other								16,166,984
Gain (Loss) on Extinguishment of Debt (in Dollars)										$ (21,892)
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											500,000,000	100,000	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		100,000,000	30,000,000	25,000,000	25,000,000

NOTE 9 - STOCKHOLDERS' EQUITY_3

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Option Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Schedule of Option Activity [Abstract]
Options Outstanding		112,970,693
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 0.03294
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 73 days	8 years 255 days
Options exercisable	64,778,655
Options exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 0.02892
Options exercisable, Weighted-Average Remaining Contractual Term	5 years 292 days
Available for grant	41,668,070
Options Granted	33,400,000
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 0.0057
Options Granted, Weighted-Average Remaining Contractual Term	10 years
Options Exercised	0
Options Forfeited/Expired	(25,332,038)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 0.02516
Options Outstanding	121,038,655
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 0.02663

NOTE 9 - STOCKHOLDERS' EQUITY_4

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Options Outstanding and Exercisable by Exercise Price Range	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 292 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.02701
Options Outstanding (in Shares) | shares	121,038,655
Options Exercisable (in Shares) | shares	64,778,655
Options Exercisable, Weighted-Average Exercise Price	$ 0.02964
Options, $0.0043 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.0043
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 18 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.0043
Options Outstanding (in Shares) | shares	13,600,000
Options Exercisable (in Shares) | shares	8,050,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0043
Options, $0.00557 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.00557
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 339 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.00557
Options Outstanding (in Shares) | shares	23,400,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.00557
Options, $0.0196 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.0196
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 124 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.0196
Options Outstanding (in Shares) | shares	21,550,000
Options Exercisable (in Shares) | shares	19,050,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0196
Options, $0.02511 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.02511
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 251 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.02511
Options Outstanding (in Shares) | shares	9,000,000
Options Exercisable (in Shares) | shares	9,000,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.02511
Options, $0.02576 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.02576
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 313 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.02576
Options Outstanding (in Shares) | shares	2,220,000
Options Exercisable (in Shares) | shares	555,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.02576
Options, $0.03626 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.03626
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 160 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.03626
Options Outstanding (in Shares) | shares	28,095,000
Options Exercisable (in Shares) | shares	19,985,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.03626
Options, $0.0536 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.0536
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 248 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.0536
Options Outstanding (in Shares) | shares	22,500,000
Options Exercisable (in Shares) | shares	7,500,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0536
Options, $0.15402 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.15402
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 120 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.15402
Options Outstanding (in Shares) | shares	673,655
Options Exercisable (in Shares) | shares	638,655
Options Exercisable, Weighted-Average Exercise Price	$ 0.15402

NOTE 9 - STOCKHOLDERS' EQUITY_5

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Schedule of Warrants Activity [Abstract]
Warrants Outstanding		1,114,019
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 14.735
Warrants Outstanding, Weighted-Average Remaining Contractual Term	8 years 146 days	9 years 36 days
Warrants Exercisable	1,110,706
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 3.24
Warrants Exercisable, Weighted-Average Remaining Contractual Term	8 years 146 days
Warrants Issued	0
Warrants Exercised	0
Warrants Expired	(1,768)
Warrants Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 532.10
Warrants Outstanding	1,112,251
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 13.91

NOTE 9 - STOCKHOLDERS' EQUITY_6

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 13.91		$ 14.735
Warrants Outstanding, Shares (in Shares)	1,112,251		1,114,019
Warrants Outstanding, Weighted- Average Remaining Contractual Term	8 years 146 days	9 years 36 days
Warrants Exercisable, Weighted- Average Exercise Price	$ 13.91
Warrants Exercisable, Shares (in Shares)	1,110,706
Warrants Exercisable, Weighted- Average Exercise Price	$ 3.24
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	1,086,536
Warrants Outstanding, Weighted- Average Remaining Contractual Term	8 years 6 months
Warrants Exercisable, Weighted- Average Exercise Price	$ 1.267
Warrants Exercisable, Shares (in Shares)	1,086,536
Warrants Exercisable, Weighted- Average Exercise Price	$ 1.27
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member] | Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	0.01
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member] | Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 20
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	19,543
Warrants Outstanding, Weighted- Average Remaining Contractual Term	4 years 146 days
Warrants Exercisable, Weighted- Average Exercise Price	$ 25.06
Warrants Exercisable, Shares (in Shares)	19,543
Warrants Exercisable, Weighted- Average Exercise Price	$ 25.06
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member] | Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	20.01
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member] | Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 30
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	2,253
Warrants Outstanding, Weighted- Average Remaining Contractual Term	3 years
Warrants Exercisable, Weighted- Average Exercise Price	$ 48.83
Warrants Exercisable, Shares (in Shares)	2,253
Warrants Exercisable, Weighted- Average Exercise Price	$ 48.83
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member] | Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	40.01
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member] | Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 50
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	543
Warrants Outstanding, Weighted- Average Remaining Contractual Term	1 year 292 days
Warrants Exercisable, Weighted- Average Exercise Price	$ 60
Warrants Exercisable, Shares (in Shares)	543
Warrants Exercisable, Weighted- Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member] | Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	50.01
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member] | Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 60
Warrants Outstanding, Shares (in Shares)	3,376
Warrants Outstanding, Weighted- Average Remaining Contractual Term	3 years 109 days
Warrants Exercisable, Weighted- Average Exercise Price	$ 398,874
Warrants Exercisable, Shares (in Shares)	1,831
Warrants Exercisable, Weighted- Average Exercise Price	$ 865.62

NOTE 10 - COMMITMENTS AND CON_2

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Jun. 15, 2019	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
General Insurance Expense		$ 11,000	$ 100,000
Litigation Settlement, Expense		$ 100,000
Settlement Liabilities, Current				$ 89,000	$ 89,000
Long-term Debt, Term	5 years
Debt Instrument, Interest Rate, Stated Percentage	5.25%
Debt Instrument, Face Amount	$ 500,000
Debt Instrument, Periodic Payment	$ 5,000

NOTE 12 - SUBSEQUENT EVENTS (De

NOTE 12 - SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]	1 Months Ended
	Oct. 31, 2019USD ($)shares
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals (in Dollars) | $	$ 269.54
Stock Issued During Period, Shares, Other	1,692,353
Paid-in-Kind Interest (in Dollars) | $	$ 9,195.12
Stock Issued During Period, Shares, Issued for Services	5,011,747
Stock Issued During Period, Shares, New Issues	2,661,935